Pulmatrix Inc has been granted two patents from the US Patent and Trademark Office (US Patent # 8,992,983 and US patent # 9,061,352), which cover the composition of matter for the company’s underlying iSPERSE (inhaled Small Particles Easily Respirable and Emitted) inhaled dry powder technology as well as methods for treating a subject using respirable dry powders.
The proprietary combination of salts and amino acids has been engineered to create small and dense particles possessing properties that have the potential to enable or improve new approaches for the treatment of lung disease or facilitate greater efficiency in the delivery of pharmaceuticals to the lungs.
Pulmatrix Issued Patents for Treatment with Inhaled Dry Powders
